Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).

Maria Gay, Francesca; Foà, Robin; Musto, Pellegrino; Cerrato, Chiara; Gamberi, Barbara; Zamagni, Elena; Palmas, Angelo; Spadano, Antonio; Omedè, Paola; Caravita, Tommaso; Giuliani, Nicola; Ballanti, Stelvio; Patriarca, Francesca; Troia, Rossella; Gentile, Massimo; Desabbata, Giovanni; Canepa, Letizia; Palumbo, Antonio; Cavo, Michèle; Boccadoro, Mario

doi:10.1200/jco.2018.36.15_suppl.8009

Public

Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).

Published in Journal of Clinical Oncology • May 20, 2018

Authors:

Francesca Maria Gay

Robin Foà

Pellegrino Musto

Abstract

8009 Background: Carf plus Len-Dex (KRd) or Cyclo-Dex (KCd) is effective in NDMM. Treatment of high-risk pts is an unmet medical need. Methods: NDMM pts ≤65 yrs were randomized (1:1:1; stratification ISS and age) to ARM A: 4 28-day induction cycles with KCd (Carf: 20/36 mg/m2 IV days 1,2,8,9,15,16; ...

Subject

Medicine

Lenalidomide

Carfilzomib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!